-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating

Benzinga·08/24/2026 10:34:30
Listen to the news
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Overweight rating.